Envestnet Asset Management
HRTX icon

Envestnet Asset Management’s Heron Therapeutics HRTX Stock Holding History

Envestnet Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9K Buy
+13,591
New +$15.7K ﹤0.01% 4697
2025
Q4 		– Sell
-14,780
Closed -$18.6K – 4548
2025
Q3 		$18.6K Sell
14,780
-3,684
-20% -$5.84K ﹤0.01% 4495
2025
Q2 		$38.2K Sell
18,464
-466
-2% -$952 ﹤0.01% 4395
2025
Q1 		$41.6K Buy
18,930
+1,182
+7% +$2.29K ﹤0.01% 4302
2024
Q4 		$27.2K Sell
17,748
-10,092
-36% -$16.4K ﹤0.01% 4280
2024
Q3 		$55.4K Buy
27,840
+8,683
+45% +$20.7K ﹤0.01% 4173
2024
Q2 		$67K Buy
19,157
+1,158
+6% +$3.56K ﹤0.01% 4088
2024
Q1 		$49.9K Buy
17,999
+4,576
+34% +$11.5K ﹤0.01% 4108
2023
Q4 		$22.8K Buy
13,423
+3,291
+32% +$3.62K ﹤0.01% 4017
2023
Q3 		$10.4K Buy
+10,132
New +$14.4K ﹤0.01% 3994
2022
Q1 		– Sell
-11,796
Closed -$108K – 3990
2021
Q4 		$108K Buy
+11,796
New +$120K ﹤0.01% 3756
2020
Q1 		– Sell
-55,406
Closed -$1.3M – 3045
2019
Q4 		$1.3M Buy
55,406
+2,427
+5% +$53.7K ﹤0.01% 1859
2019
Q3 		$980K Buy
52,979
+4,247
+9% +$78.2K ﹤0.01% 1957
2019
Q2 		$906K Sell
48,732
-2,200
-4% -$43.9K ﹤0.01% 2013
2019
Q1 		$1.25M Buy
50,932
+6,047
+13% +$158K ﹤0.01% 1753
2018
Q4 		$1.16M Buy
+44,885
New +$1.23M ﹤0.01% 1639
2018
Q3 		– Sell
-1,337
Closed -$52K – 1856
2018
Q2 		$52K Sell
1,337
-2
-0.1% -$64 ﹤0.01% 2197
2018
Q1 		$37K Buy
+1,339
New +$30.4K ﹤0.01% 2227

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Envestnet Asset Management's HRTX Position: Q1 2026 in Review

Envestnet Asset Management opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 13,591 shares worth $10.9K. The stake represents ﹤0.01% of the portfolio and ranks #4697 among its holdings. This is a return to the name: Envestnet Asset Management previously reported a position in HRTX as recently as Q3 2025.

Envestnet Asset Management first reported a position in HRTX in Q1 2018 and has held it in 18 quarters since. The position peaked at $1.3M in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Envestnet Asset Management held 13,591 shares of Heron Therapeutics worth $10.9K as of Q1 2026.
  • Heron Therapeutics was a new Envestnet Asset Management position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #4697 holding.
  • Envestnet Asset Management first reported a position in Heron Therapeutics in Q1 2018 and has held it in 18 quarters since.
  • Envestnet Asset Management's Heron Therapeutics position peaked at $1.3M in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.